Anaptysbio (ANAB) Liabilities and Shareholders Equity (2016 - 2026)

Anaptysbio's Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $329.7 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 21.89% year-over-year to $329.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 24.32% YoY) and the FY2025 annual result came in at $364.4 million, down 24.69% from the prior year.
• Liabilities and Shareholders Equity was $329.7 million for Q1 2026 at Anaptysbio, down from $364.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $625.2 million in Q1 2022 and bottomed at $329.7 million in Q1 2026.
• A 5-year average of $475.4 million and a median of $483.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 57.7% — and 2025, when it retreated 28.44%.
• Anaptysbio's Liabilities and Shareholders Equity stood at $610.4 million in 2022, then decreased by 25.88% to $452.4 million in 2023, then rose by 6.95% to $483.8 million in 2024, then slipped by 24.69% to $364.4 million in 2025, then slipped by 9.53% to $329.7 million in 2026.
• Business Quant data shows ANAB's Liabilities and Shareholders Equity at $329.7 million in Q1 2026, $364.4 million in Q4 2025, and $353.1 million in Q3 2025.